Innovent Announces 2025 Annual Results and Business Updates Consequently, actual results may differ materially from information contained in the forward-looking statements as a result of future changes or developments in our business, Innovent's
Innovent Announces 2025 Annual Results and Business Updates Consequently, actual results may differ materially from information contained in the forward-looking statements as a result of future changes or developments in our business, Innovent's competitive environment and political, economic, legal and social conditions
Innovent Announces 2025 Annual Results and Business Updates Innovent Biologics, Inc (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic
Innovent Biologics 2025 Annual Results Disclaimer This presentation includes forward-looking statements All statements contained in this presentation other than statements of historical facts, including statements regarding future results of operations and financial position of Innovent Biologics (“Innovent” “we,” “us” or “our”), our business strategy and plans, the clinical development of our product candidates
Innovent Announces 2025 Interim Results and Business Updates . . . Robust revenue growth and substantial profit improvement Continued exceptional executions under a clear roadmap of dual-driven growth and global innovation SAN FRANCISCO and SUZHOU, China, Aug 27, 2025 PRNewswire -- Innovent Biologics, Inc (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the